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Abstract
Background: Public Health England (PHE) estimates that there are upwards of 160,000 individuals in England and
Wales with chronic hepatitis C virus (HCV) infection, but until now only around 100,000 laboratory diagnoses have
been reported to PHE and of these 28,000 have been treated. Targeted case-finding in primary care is estimated to
be cost-effective; however, there has been no robust randomised controlled trial evidence available of specific
interventions. Therefore, this study aims to develop and conduct a complex intervention within primary care and to
evaluate this approach using a cluster randomised controlled trial.
Methods/design: A total of 46 general practices in South West England will be randomised in a 1:1 ratio to receive
either a complex intervention comprising: educational training on HCV for the practice; poster and leaflet display in
the practice waiting rooms to raise awareness and encourage opportunistic testing; a HCV risk prediction algorithm
based on information on possible risk markers in the electronic patient record run using Audit + software (BMJ
Informatica). The audit will then be used to recall and offer patients a HCV test. Control practices will follow usual
care. The effectiveness of the intervention will be measured by comparing number and rates of HCV testing, the
number and proportion of patients testing positive, onward referral, rates of specialist assessment and treatment in
control and intervention practices. Intervention costs and health service utilisation will be recorded to estimate the
NHS cost per new HCV diagnosis and new HCV patient initiating treatment. Longer-term cost-effectiveness of the
intervention in improving quality-adjusted life years (QALYs) will be extrapolated using a pre-existing dynamic
health economic model. Patients’ and health care workers’ experiences and acceptability of the intervention will be
explored through semi-structured qualitative interviews.
Discussion: This trial has the potential to make an important impact on patient care and will provide high-quality
evidence to help general practitioners make important decisions on HCV testing and onward referral. If found to be
effective and cost-effective the intervention is readily scalable and can be used to support the implementation of
NICE recommendations on HCV case-finding.
Trial registration: ISRCTN61788850. Registered on 24 April 2015; Protocol Version: 2.0, 22 May 2015.
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Background
Hepatitis C (HCV) infection is an important contribu-
tor to the growing burden of liver disease in the UK
[1]. Infection results in cirrhosis and associated life-
threatening complications in around 20 % of infected
individuals over an average period of 20–30 years [2].
The risk factors for HCV infection include past or
current injecting drug use, and being born or having
lived in countries with a high prevalence of infection,
where infection may have been acquired vertically, or
through health care interventions. Approximately 90 %
of infections acquired in the UK are among people who
inject drugs (PWID) or who have injected drugs in the
past [3]. Viral hepatitis, including HCV, is the only
major cause of liver disease which is manageable or
curable with recently developed therapies, as well as be-
ing preventable. HCV case-finding and uptake of treat-
ment [4], however, need to be improved.
The sentinel surveillance of the Hepatitis Annual Re-
port shows that general practice is the single most im-
portant setting for HCV testing (30 % of all tests
originate here) and for identifying positive patients (31 %
of all positive results are generated here). There is lim-
ited evidence from a small uncontrolled study in eight
practices that targeted case-finding in primary care can
increase the proportion of eligible individuals being
tested for HCV by a factor of three and the proportion
of positive tests amongst individuals tested by a factor of
five [5]. The intervention involved offering practice staff
training on the epidemiology, diagnosis and manage-
ment of HCV infection, introducing an electronic pa-
tient record search to identify individuals at higher risk
of HCV infection, and the offer of a HCV test to higher-
risk individuals.
The intervention was used as the basis of a cost-
effectiveness model of HCV case-finding in primary care
used by the National Institute for Health and Care Ex-
cellence (NICE) [6]. Increasing testing in primary care
(among those aged 30–54) was cost-effective at an esti-
mated incremental cost-effectiveness ratio (ICER) of
£13,900 per quality-adjusted life year (QALY) (79 to
93 % likely to be cost-effective at £20,000 and £30,000
per QALY gained willingness-to-pay thresholds). The
intervention was more cost-effective if PWID who had
an ongoing risk of transmitting HCV to other people
were also tested and treated, and if the baseline testing
rate was higher than expected. An additional potential
benefit of this approach is that it may also identify pa-
tients who had already been diagnosed, but had not been
referred for further management, offering an opportun-
ity for reconsideration of such referrals [7].
In the US, a population-based approach has been
adopted to identify HCV-infected individuals. Instead of
risk-based testing, two individual models were evaluated
based on membership of the 1945–1965 birth cohort or
the presence of elevated levels of serum alanine amino-
transferase (ALT) [8]. The birth cohort strategy was esti-
mated to be cost-effective above a threshold HCV
prevalence of 0.53 % which exceeds UK HCV prevalence
and so is unlikely to be cost-effective in the UK [9]. ALT
screening was previously investigated in a German study
where primary care patients with an elevated ALT level
of 50–100 IU/l had a HCV prevalence 10-fold above the
population prevalence [10]. Since this study, the pres-
ence of one of the three significant risk factors for HCV
(intravenous drug use, blood transfusion pre 1992 and
immigration) or of elevated ALT levels has been shown
to diagnose 83 % of unknown HCV-ribonucleic acid
(RNA)-positive cases by screening only a quarter of the
population studied [11]. The effectiveness of risk-based
testing on its own in routine clinical practice is still
under much debate. For example, individuals who have
occasionally injected drugs in the remote past will prob-
ably not seek treatment for injecting drug use. Further-
more, they may be unlikely to disclose their risk status
in a consultation with their general practitioner (GP). It
has been estimated that from the total population of
HCV-infected individuals in a high-income country, only
34 % are easily identifiable in high-risk groups such as a
history of being injecting drug users or first-generation
migrants [12]. Therefore, the hidden population of
HCV-infected individuals may be significant and should
be considered when developing future search strategies.
We aim to conduct a complex intervention study in pri-
mary care to identify patients who are at higher risk of
HCV or patients who have a history of apparently untreated
HCV and invite them to undergo testing. We will evaluate
this approach using a cluster randomised controlled trial
with qualitative and health economic components.
Methods/design
Study design
The study will consist of a pragmatic, two-arm, practice-
level, cluster randomised controlled trial with a nested
qualitative study and economic evaluation.
Ethics approval for the design described here was re-
ceived from the National Research Ethics Service
(NRES) Committee South West-Frenchay (Reference:
15/SW/0094) and research governance approvals ob-
tained across all areas which will be involved in the
study. The West of England National Institute for Health
Research Clinical Research Network (NIHR CRN) will
assist in identifying and accessing GP practices in the
South West of England to participate in the trial. Inter-
ested practices will be contacted by the trial coordinator
who will arrange a meeting with the practice manager,
GP partners and practice nurse(s). Since this is a cluster
randomised trial, and all patients within one practice will
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be treated in the same way, consent will be obtained
from practices. Patients will not provide individual con-
sent to participate in the intervention, though a purpose-
ful sample will be asked for consent to participate in the
nested qualitative study. See Fig. 1 for trial schema.
GP practices will be the unit of allocation. Practices will
be randomised by an independent statistician in a 1:1 ratio
to receive either the intervention or continue care as usual
(control group). Randomisation will be stratified by area
(Bristol, non-Bristol) and current rate of HCV testing
(high: ≥1 % of the practice list versus low: <1 %), and mini-
mised by practice size. In 93 practices in our target area,
15 (16 %) had HCV high testing rates.
Participant eligibility
Qualitative study
Patients must be:
 Registered with one of the participating intervention
practices and offered a HCV test
Fig. 1 Trial schema and flow diagram
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 Aged 18 years or over, able to provide consent and
have access to a telephone
Sample size
We based our initial sample size calculation on an aver-
age practice of 6500; with 4225 adults aged 15–65, we
would expect approximately 1 % (42) of people to have
an injecting history and in Bristol approximately 40 %
(17) of those to have chronic HCV [13]. As a minimum
we assume that 10 high-risk patients, based on the algo-
rithm and markers of previous injecting history, will be
identified and that the intervention increases uptake of
HCV testing from 5 to 17 % of those high-risk patients.
Then we require a sample size of 46 practices (23 inter-
vention and 23 control, 230 high-risk patients identified
in each arm) to achieve 90 % power at the 5 % signifi-
cance level. We have assumed an intra-cluster correl-
ation coefficient (ICC) of 0.05, and hence a design effect
of 1.45, to accommodate variation in testing rates across
practices.
This is a conservative sample size calculation to ensure
a large enough number of practices and sufficient power
to measure the main intervention effect on uptake of
HCV case-finding and diagnosis as well as referral and as-
sessment for treatment. First, practices being approached
for the study and identified by the CRN have an average
practice list size of 10,000 and, therefore, approximately
6500 adults aged 15–65. Second, it is likely that 2 % of
adults will have an injecting history – combining estimates
of people currently on opioid substitution treatment and
ex-injecting drug users [14, 15]. Third, early pilot studies
suggest that it is likely that 80 or more people for an aver-
age practice will be identified by the algorithm. This gives
approximately 1840 people per arm and substantial power
to detect a difference in uptake of HCV testing. In
addition, if we assume that two thirds of people diagnosed
with chronic HCV attend hepatology for assessment then
the case-finding rates of 5 and 17 % convert to HCV treat-
ment readiness rates of 1.3 and 4.4 % and 72 % power
(with an ICC of 0.05) to detect a true difference in HCV
treatment readiness. As we will adjust the statistical ana-
lysis for testing rate and whether a practice is within or
outside the Bristol area, this will accommodate some of
the clustering, and so it is likely that we will have sufficient
power to detect a difference in HCV treatment assessment
as well as HCV testing uptake.
Planned interventions
Educational training on HCV
Participating practices will be offered a 1-hour educa-
tional presentation on HCV and trial procedures, includ-
ing instructions on how to use the Audit + software
(BMJ Informatica), which will be delivered by the trial
coordinator at the practice. The practice will also be sent
information about free online HCV educational re-
sources (such as the RCGP e-learning module). All staff
at the practice will be invited to attend the training ses-
sion; however, if any members of staff cannot attend the
pre-arranged date then the training can be cascaded
within the practice.
Increasing patient awareness
Posters and leaflets will be displayed in the practice wait-
ing room explaining risk factors for HCV infection. Prac-
tices will also be encouraged to include an additional
question ‘have you ever injected drugs?’ to the new patient
registration proforma. A positive answer would lead to
discussion of testing at the next consultation.
Identification of patients with risk markers of HCV or
patients previously diagnosed
The Audit + software (BMJ Informatica) will be used to
assist practices in identifying patients with high-risk
HCV markers or patients previously diagnosed who
failed to initiate or complete treatment. Audit + is an in-
tegrated piece of software which is compatible with mul-
tiple GP clinical platforms and will have the HCV test
algorithm or ‘audit’ built in. Audit + has been used in
previous non-HCV-related studies and shown to reduce
the number of patients ‘at risk and unscreened’ by al-
most two thirds [16]. We selected Audit + because it was
becoming familiar to practices and was scalable.
The practice manager will be asked to install the
Audit + software onto the practices’ clinical system. Prac-
tice staff training will include details on how to install
and use the Audit + software as part of the intervention.
Within the Audit + software, the HCV audit will be used
to identify potentially eligible patients who have pre-
defined Read codes defining them as ‘high-risk’ (see
Appendix). The Audit + software identifies all patients
with one or more of the codes. Patients excluded are
those: tested recently for HCV; who have been referred
to hepatology; receiving palliative care; who have raised
ALT and tested for HCV. The audit will be run and up-
dated every 24 hours on the GP system. GPs will be
asked to screen the resultant list at the beginning of the
intervention and then regularly, at intervals defined by
the practice, to identify new patients during the remain-
der of the study period. GPs will be permitted to exclude
any patient identified by the audit where they feel that
an invitation for HCV testing or discussion of treatment
is not appropriate. Eligible patients’ records identified by
the audit will be automatically flagged by the software to
encourage opportunistic testing if the patient attends the
surgery. Practice staff can manually switch off the flag-
ging should they feel that the patient is not eligible for a
HCV test, if the patient declines a test or if the patient
accepts the offer of a test, by entering a specific set of
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Read codes. Practice staff administrators will also be
asked to send out a letter to each patient identified by
the audit informing them that the practice is taking part
in a study and that they may contact patients by tele-
phone, e-mail or text (whichever is preferred by the
practice) to book an appointment to discuss having a
test. The patient invitation letters will be automatically
processed using the integrated mail-merge facilities built
within the software. Diagnosed patients are managed as
usual/in standard care at the practice.
Control practices
The control practices are only contacted at the time of
randomisation and their contribution to the study (col-
lection of data in 12 months’ time) is explained to them
at the set-up telephone conversation shortly after they
have been randomised. The study team do not contact
the control practices again until at the end of the inter-
vention period; control practices will be asked to install
and run a ‘dummy version’ of the audit using the Audit
+ software to search for high-risk HCV patients retro-
spectively (i.e. the same calendar period as for the inter-
vention practices). These data will be used to compare
control and intervention practices to assess the impact
of the intervention at the individual patient level as well
as at the practice level. At the end of the study period,
the control practices will be provided with the software
licence for approximately 1 year and can choose to use
any of its applications including the HCV audit.
Outcome measures and statistical analysis
Data will be collected from three separate sources:
general practices (using the Audit + software in the
intervention practices and control practices), PHE la-
boratories Bristol and specialist secondary care hepatol-
ogy services. During the study period we will also
collect data on individuals who, from the practice elec-
tronic patient record (age, sex, postcode district, HCV
risk factors as included in the algorithm) are identified
by the audit as high-risk. As patient consent is not ob-
tained, only anonymous data will be provided for the
University of Bristol research team. Therefore, data will
be sent by staff at the general practices and secondary
care services to a data analyst at PHE laboratories. The
data will then be linked using NHS numbers, GP code,
name and date of birth, and anonymised and assigned a
unique study ID number before sending the data to the
research team at the University of Bristol.
Primary outcome measures
 The number and proportion of high-risk patients
tested for HCV. The total number of HCV tests
performed at the intervention practices and at the
control practices during the intervention period will
be collected by PHE laboratories
Secondary outcome measures
The HCV risk factors associated with each patient iden-
tified by the audit will be recorded by the Audit + soft-
ware at participating practices. We will assess:
 Number and proportion of high-risk patients testing
HCV antibody positive and HCV RNA positive. The
results of each screening HCV test at each of the
participating practices will be collected by PHE
laboratories. Follow-up tests including polymerase
chain reaction (PCR) (which diagnoses chronic
HCV) and viral load results will also be collected by
PHE laboratories
 Number and proportion of high-risk patients referred
for specialist assessment. This will be recorded by
data held by PHE laboratories for each of the
participating practices
 Number and proportion of high-risk patients attending
their initial assessment (and fibroscan conducted).
This will be obtained from the secondary care
hepatology records at University Hospitals Bristol
and North Bristol Trusts and sent to PHE laboratories
for linkage
 Number and proportion of high-risk patients initiating
treatment. These data will be recorded by the
secondary care hepatology records at University
Hospitals Bristol and North Bristol Trusts and sent
to PHE laboratories for linkage
The proportion of high-risk people tested for HCV,
compared between intervention and control arms as a
rate ratio, will be estimated in a negative binomial re-
gression model, adjusted for whether an individual’s
practice is in Bristol or not, and whether that practice
has at baseline a high HCV testing rate or not. This re-
gression model accommodates variation in the outcome
measure between GP practices. This approach will be
adapted to the secondary outcome measures, and also to
estimate the risk difference between intervention and
control arms for the primary outcome measure. These
analyses will follow the intention-to-treat principle, with
practices being analysed in the arms to which they are
randomised.
Health economics
We aim to estimate the short-term cost-effectiveness of
the case-finding intervention from the NHS perspective.
The research team will use a proforma to record the
number of practices who accept the educational presen-
tation on HCV, including the number of practice staff at-
tending and job titles. Practice staff will be provided
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with a proforma to record the time taken to extract and
screen the lists of high-risk patients and to exclude ineli-
gible patients each time the Audit + search is run. The
proforma will also ask practice staff to record the number
of letters sent out to patients inviting them to book an ap-
pointment. At both intervention and control sites practice
staff will extract information from the electronic patient
record on the consultations, laboratory tests, radiology
and prescriptions received by patients during the study
period identified as high-risk by Audit +. This dataset will
be de-identified and assigned a unique study ID by a data
analyst at PHE laboratories, as described above.
This will allow us to identify HCV case-finding consulta-
tions (in the intervention practices) and opportunistic
HCV testing consultations (in intervention and control
practices). We will also use the linked dataset to identify
post-diagnosis resource use (e.g. follow-up consultations
with GPs and specialists, prescriptions). Where available,
national unit costs [17, 18], or locally estimated unit costs if
unavailable, will be used to value the time spent inviting pa-
tients to case-finding appointments and delivering HCV-
related care to high-risk and untreated patients throughout
the study period. We will calculate the incremental cost
per new diagnosis of HCV and the incremental cost per
new patient initiating HCV treatment in intervention ver-
sus control practices. Uncertainty will be explored using
cost-effectiveness acceptability curves, which estimate the
probability of intervention cost-effectiveness for various
willingness-to-pay thresholds [19].
Provided that the intervention improves case-finding
and treatment, we will extrapolate short-term costs and
outcomes of the intervention using a health economic
model that is parameterised to the UK health provider
perspective including liver disease progression stages and
QALYs used in previous exercises for NICE and the Hu-
man Tissue Authority (HTA) [7, 20–22]. The model also
can be dynamic, incorporating the potential prevention
benefit of diagnosing and treating people who inject drugs
as well as people who have ceased injecting or other pa-
tient groups. Costs and health benefits are discounted at
3.5 % per year in the base case according to NICE guide-
lines. Results will be expressed in terms of incremental
cost-effectiveness ratios (ICERs), calculated by dividing
the difference in costs between the intervention and usual
care strategies, divided by the difference in health out-
comes, in this case QALYs. For each economic analysis,
multivariate uncertainty analyses and numerous one-way
sensitivity analyses will be undertaken so that the robust-
ness of the model results can be examined; and we will
also plot cost-effectiveness acceptability curves.
Qualitative interviews
Health care professionals (HCPs) and patients’ views and
experiences of the intervention will be examined
through the conduct of semi-structured qualitative inter-
views. The qualitative findings will assist in highlighting
the perceived effectiveness and acceptability of targeted
HCV case-finding and increasing HCP and patient
awareness within primary care.
Qualitative study design
Qualitative telephone interviews will be conducted
with primary care patients and the interviews will con-
sider and compare (1) views and experiences of being
approached opportunistically at the practice or con-
tacted by letter and invited for a consultation with
their GP, (2) the acceptability of being approached for
a HCV test, (3) views on whether any additional inter-
ventions may be helpful, and (4) (if tested HCV-
positive) views and experiences of referral to secondary
care and on-going assessment/treatment.
HCPs involved at the intervention practices will also
be interviewed to gather data on (1) their views and
experiences, (2) changes in clinical practice, (3) accept-
ability and feasibility of the intervention, (4) informa-
tion and support needs, and (5) their attitudes to the
future implementation of the intervention within pri-
mary care.
Interview participant sampling and recruitment
Patients offered a HCV test at participating intervention
practices will be asked if they are willing to be contacted
about taking part in a qualitative interview at the time of
their consultation. From participants who indicate that
they are willing to be contacted, a purposive sample will
be drawn in relation to (1) primary care practice, and (2)
socio-demographic variables (e.g. gender, age and ethni-
city). Telephone interviews will be conducted with a
sample of patients who (1) declined a HCV test, (2) ac-
cepted a HCV test, (3) tested positive for HCV and were
subsequently referred to secondary care. HCP (including
general practitioners and nurses) involved in implement-
ing the intervention will be purposively sampled in rela-
tion to (1) primary care practice, (2) professional role,
and (3) length of time since qualification/seniority.
Those sampled will be contacted by the researcher and
asked if they are interested in taking part in an inter-
view. Patients will be interviewed either after they have
been offered a HCV test or for patients who have
already tested positive for HCV before the study, a sam-
ple of these will be interviewed following their first at-
tendance for assessment and/or treatment. The sample
sizes will be determined by the need to achieve data sat-
uration, such that no new themes are emerging from the
data by the end of data collection [23]. This is likely to
include up to 15 HCPs and 15 patients at participating
intervention practices.
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Interview conduct
All interviews will be conducted by telephone. Partici-
pants will be asked to provide their verbal informed con-
sent to take part immediately before the interview. A
flexible topic guide will be used in order to assist ques-
tioning during in-depth individual interviews. Topic
guides will be modified as necessary throughout the
course of the study to reflect findings as they emerge.
With informed consent from participants, interviews will
be audio-recorded using a digital voice recorder, tran-
scribed and anonymised to protect confidentiality.
Qualitative data analysis
Interview transcripts will be checked for accuracy and
then imported into NVivo10 qualitative data analysis
software to aid management and analysis of data. Ana-
lysis will begin shortly after data collection starts and
will be ongoing and iterative. Analysis will inform fur-
ther data collection: for instance, analytic insights from
data gathered in earlier interviews will help identify any
changes that need to be made to the topic guide during
later interviews. Thematic analysis [24], utilising a data-
driven inductive approach will be used to scrutinise the
data in order to identify and analyse patterns and themes
of particular salience for participants and across the
dataset.
Discussion
This trial has the potential to make an important impact
on patient care and will provide high-quality evidence to
help general practitioners make important decisions on
HCV testing and onward referral. The intervention is
scalable and, therefore, if found to be effective and cost-
effective can be readily rolled out and implemented else-
where in the UK in response to new NICE recommenda-
tions on improving HCV case-finding.
Trial status
At the time of manuscript submission, this trial was still
in the practice recruitment phase.
Appendix
HCV audit
A HCV test algorithm was developed and piloted at two
local general practices before its integration into the
Audit + software (BMJ Informatica). The HCV test algo-
rithm was designed to identify registered patients with
high-risk HCV markers or patients previously diagnosed
who failed to initiate or complete treatment. The search
terms included (1) age 18–75 years old, (2) previous
intravenous drug use (IDU) history, (3) opiate prescrip-
tion (including methadone or buprenorphine), (4) opiate
misuse, (5) blood transfusion prior to 1991, (6) blood
products prior to 1996, (7) transplant prior to 1992, (8)
infection with HIV, (9) infection with hepatitis B virus
(HBV), (10) born to a mother with HCV, (11) child in
care, (12) prison history, (13) altered ALT levels, (14) pa-
tients tested for HCV over 1 year previous, before the
intervention. Identified individuals considered by GPs to
be unsuitable for a discussion about HCV testing or
treatment were excluded. Patients also automatically ex-
cluded by the HCV audit included (1) patients referred
to hepatology, (2) patients tested less than 1 year prior
to the intervention, (3) patients receiving end of life/pal-
liative care, and patients with raised ALT levels who
have been tested for HCV.
The list of codes are available from the authors and
given in Additional file 1. Spirit Checklist also available
in Additional file 2.
Additional file
Additional file 1: HepCATT study algorithm (Read codes). (DOC 118 kb)
Additional file 2: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 121 kb)
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